Yondelis® Approved for Treatment of Soft Tissue Sarcoma
FDA Approves Trabectedin for Sarcoma - NCI
On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue ...
YONDELIS® is the first FDA-approved treatment for advanced soft tissue sarcoma. Learn about efficacy, side effects, risks, safety, and more.
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS® (trabectedin) for the treatment of patients with unresectable ...
Yondelis (Trabectedin) Approved for the Treatment of Unresectable ...
Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, ...
Trabectedin for Soft Tissue Sarcoma: Current Status and Future ...
Trabectedin (ET743, Yondelis®, manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ...
New Therapeutic for Treating Certain Soft Tissue Sarcomas
The FDA has approved trabectedin for the treatment of certain patients with two types of soft tissue sarcoma, liposarcoma and leiomyosarcoma.
Trabectedin (Yondelis) | Cancer information
Trabectedin (Yondelis) is a chemotherapy drug. You might have it as a treatment for soft tissue sarcoma or ovarian cancer. Find out more about how you have ...
HCP Treatment Considerations - YONDELIS®
YONDELIS® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior ...
FDA Approves Trabectedin in Soft Tissue Sarcomas - OncLive
The FDA has approved trabectedin for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma ...
Trabectedin for Soft Tissue Sarcoma: Current Status and ... - PubMed
Trabectedin (ET743, Yondelis(®), manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), ...
FDA Approves Trabectedin (Yondelis) for Advanced Soft-Tissue ...
The FDA announced the approval of trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or ...
Yondelis® Approved for Treatment of Soft Tissue Sarcoma
Yondelis® Approved for Treatment of Soft Tissue Sarcoma. The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® ( ...
Yondelis (trabectedin) FDA Approval History - Drugs.com
FDA approval history for Yondelis (trabectedin) used to treat Soft Tissue Sarcoma. Supplied by Janssen Biotech, Inc.
FDA Approves New Therapeutic for Treating Certain Soft Tissue ...
Specifically, trabectedin is approved for treating patients with liposarcoma and leiomyosarcoma that cannot be removed by surgery or that is ...
Yondelis | European Medicines Agency (EMA)
Therapeutic indication. Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide ...
U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for ...
U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma · RARITAN, NJ, ...
FDA Approves Trabectedin for Advanced Liposarcoma and ...
The U.S. Food and Drug Administration has approved the novel chemotherapy drug trabectedin (Yondelis) for the treatment of specific ...
Trabectedin (Yondelis) - Medical Clinical Policy Bulletins - Aetna
Trabectedin (Yondelis) is an alkylating drug. U.S. Food and Drug Administration (FDA)-Approved Indications. Yondelis is indicated for the treatment of patients ...
Novel Antitumor Agent "Yondelis® IV Infusion" Approved in Japan ...
Taiho Pharmaceutical believes that Yondelis will contribute to the treatment of patients, as a new treatment option for soft tissue sarcoma, an ...
A randomized phase III trial comparing trabectedin to best ...
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial